Загрузка...
Plasma microRNA alterations between EGFR-activating mutational NSCLC patients with and without primary resistance to TKI
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have obtained excellent therapeutic effects against non-small cell lung cancer (NSCLC) harboring activating EGFR mutations. However, some patients have exhibited primary resistance which becomes a major obstacle in effective t...
Сохранить в:
| Опубликовано в: : | Oncotarget |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Impact Journals LLC
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5687624/ https://ncbi.nlm.nih.gov/pubmed/29179454 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19874 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|